Stay updated on Pembrolizumab as AML Post-Remission Treatment Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    Revision tag updated from v3.4.3 to v3.5.0.
    Difference
    0.1%
    Check dated 2026-03-18T15:44:50.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    Added Revision: v3.4.3 and removed Revision: v3.4.2 from the page metadata.
    Difference
    0.1%
    Check dated 2026-03-11T14:48:04.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    The new screenshot shows minor layout and styling updates (e.g., spacing and header tweaks). There are no changes to core study data such as eligibility criteria, outcomes, enrollment, or results.
    Difference
    0.1%
    Check dated 2026-02-18T04:14:22.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    Site updated to version v3.4.2. The prior government funding notice was removed; there are no changes to the trial details or page data.
    Difference
    0.5%
    Check dated 2026-02-11T01:53:10.000Z thumbnail image
  8. Check
    70 days ago
    Change Detected
    Summary
    A site-wide notice about government funding affecting updates was added, and the site version was updated to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2026-02-03T23:21:55.000Z thumbnail image
  9. Check
    77 days ago
    Change Detected
    Summary
    Minor UI/copy updates include showing the glossary option, capitalization tweaks in the QC criteria wording, and a new revision/version line. These changes are cosmetic and do not affect study content or navigation.
    Difference
    0.2%
    Check dated 2026-01-27T20:40:40.000Z thumbnail image

Stay in the know with updates to Pembrolizumab as AML Post-Remission Treatment Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.